Sarah McFarlane

1 week ago | healtheconomics.com | Sarah McFarlane

Pfizer has entered into an exclusive global licensing agreement, excluding China, with 3SBio Inc., a leading Chinese biopharmaceutical company, to develop, manufacture, and commercialize SSGJ-707. This bispecific antibody, targeting PD-1 and VEGF, is undergoing clinical trials in China for various cancers, including non-small cell lung cancer and colorectal cancer.

2 weeks ago | healtheconomics.com | Sarah McFarlane

In the recent Ascent-03 trial, Gilead Sciences’ antibody-drug conjugate Trodelvy demonstrated significant efficacy by outperforming standard chemotherapy in prolonging progression-free survival in patients with previously untreated metastatic triple-negative breast cancer (TNBC). This trial focused on patients not eligible for PD-1 or PD-L1 inhibitors due to lack of PD-L1 protein expression or ineligibility for immunotherapy.

2 weeks ago | reuters.com | Sarah McFarlane |Hadeel Al Sayegh |Hadeel El Sayegh

The Saudi Aramco logo is pictured at Hyvolution exhibition in Paris, France, February 1, 2024. REUTERS/Benoit Tessier/File Photo Aramco will retain majority ownership of the assets and remain the operator - sourceJafurah potentially biggest shale gas project outside of U.S.(2222.SE), opens new tab is seeking investors in infrastructure, including pipelines, for its $100 billion LONDON, May 23 (Reuters) - Saudi oil giant Aramco Jafurah gas project, two people familiar with the matter told Reuters.

2 weeks ago | healtheconomics.com | Sarah McFarlane

Moderna has voluntarily withdrawn its application for a combined COVID-19 and influenza vaccine for adults aged 50 and older, following discussions with the U.S. Food and Drug Administration (FDA). This decision comes shortly after the FDA announced new guidelines, which will require more comprehensive efficacy data, including placebo-controlled studies, before approving COVID vaccines for healthy adults under 65.

3 weeks ago | healtheconomics.com | Sarah McFarlane

The FDA has approved the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, marking the first time a blood test can be used to aid in diagnosing Alzheimer’s disease. Intended for patients aged 55 and older who show symptoms of cognitive decline, this test identifies amyloid plaques associated with Alzheimer’s by measuring the ratio of pTau217 and β-amyloid 1-42 proteins in blood plasma.